. 2021 Oct 28;125:102743. doi: 10.1016/j.jaut.2021.102743

Table 3.

FCBF-based multivariable logistic regression analysis for risk factors associated with poor immune responses to SARS-CoV-2 vaccination.

Prominent feature^a	Regression coefficient	Odds ratio	p-value	CI low	CI upper
Mycophenolate Mofetil**	2.185	9.212,	<0.0001	3.46	24.759
Rituximab**	1.875	6.803	0.005	1.934	24.302
Comorbidities	0.664	2.0	0.139	0.942	4.254
Polymyalgia Rheumatica	−0.466	0.644	0.765	0.094	26.61
IL-1 inhibitors	−0.181	0.848	0.927	0.429	35.841
Ustekinumab	−0.181	0.848	0.927	0.438	34.363

**<0.05 (95% confidence interval): final independent risk factors associated with non-responders.

***Logistic regression equation ( $y$ denotes the outcome). $p (y) = \frac{1}{1 + e^{- (- 0.985 + 2.185 * M y c o p h e n o l a t e + 1.875 * R i t u x i m a b + 0.664 * C o m o r b i d i t i e s - 0.466 * P o l y m y a l g i a - 0.181 * I L 1 - 0.181 * U s t e k i n u m a b)}}$

Abbreviations: IL-: Interleukin.

The strongest potentially independent variables identified by the FCBF algorithm to construct the logistic regression model, after analyzing initially the following features included in the dataset: age, gender, duration of disease, disease activity before vaccination, presence of any comorbidity, no treatment, extended treatment modifications, partial treatment modifications, no treatment modifications, glucocorticoids, mycophenolate mofetil, azathioprine, methotrexate, leflunomide, hydroxychloroquine, TNF inhibitors, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, IL-17 inhibitors, rituximab, JAK inhibitors, apremilast, abatacept, belimumab, colchicine, cyclosporine, cyclophosphamide, IVIG, systemic vasculitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, idiopathic inflammatory myositis, seronegative arthritis, familial mediterranean fever, IgG4-related diseases, antiphospholipid syndrome, polymyalgia rheumatica, Bechet's disease, Still's disease and mixed connective tissue diseases.